3D Bioprinting Market Will Make A Huge Impact In Near Future

Spritam (levetiracetam) is the first treatment with 3D bioprinting that gained FDA approval and was developed by Aprecia Pharmaceutical, a specialty pharmaceutical company. Healthcare professionals are markedly exploring 3D bioprinting as it helps in reducing the risks related to anesthesia during extensive surgeries. Restrictions of the biomaterial-based products and lack of thorough automation in the 3D bioprinting, are factors probable in creating challenges for the healthcare industry, which in turn impacts 3D bioprinting market as well.

Read full article

More News